Camurus AB
CAMX
ISIN SE0007692850 / Valor 30510553
Camurus AB
UMushroom community rating:
About company
Camurus AB is a Swedish specialty pharmaceutical company that develops and commercializes long‑acting injectable medicines based on its proprietary FluidCrystal lipid‑based drug delivery technology, which is designed to provide sustained subcutaneous release of peptides and small molecules. Its most advanced commercial product is Buvidal (buprenorphine), a weekly and monthly injectable treatment for opioid use disorder that is marketed in multiple countries, and the company pursues a pipeline of clinical‑stage programs and partnered projects targeting pain, oncology and rare diseases. Camurus combines in‑house development with collaborations and regulatory filings to advance formulations that aim to improve dosing frequency and patient adherence, and it is listed on the Nasdaq Stockholm exchange.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
3450 M
Market cap (USD)
63,435
Daily traded volume (Shares)
581.5 / 567
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
